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Symbols                                 Abbreviations 
BCS - Biopharmaceutical Classification System 
DDS   -         Drug Delivery System 
RMG   -         Rapid mixer granulator 
FBP - Fluidized Bed Processor 
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GIT - Gastro Intestinal Tract 
HCl - Hydrochloric acid 
HPC - Hydroxy Propyl Cellulose 
HPLC - High Performance Liquid Chromatography 
MCC - Microcrystalline cellulose 
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NaOH - Sodium Hydroxide 
NCC - No Chemical Change 
NLT   - Not less than 
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NSAIDs -
 
Non Steroidal Anti Inflammatory Drugs 
PVP - Polyvinyl Pyrrolidone 
TI - Therapeutic Index 
USP - United States Pharmacopoeia 
ACE - Angiotension converting enzyme 
ARBs - Anti receptor blockers 
 
 
  
 
Symbols:       
# - mesh  
% - Percentage 
Ɵ -  Angle of repose 
w/w - weight by weight 
v/v  - volume by volume 
min - minute 
sec - second 
mg - milligram 
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rpm - rotations per minute 
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INTRODUCTION 
Tablets may be defined as solid pharmaceutical dosage forms containing drug 
substances with or without suitable diluents and prepared either by compression or 
molding methods. They have been in widespread use since the latter part of the 19th 
century and their popularity continues. The term compressed tablet is believed to have 
been first used by ‘John Wyeth and Philadelphinn’. During the same period molded 
tablets were introduced to be used as Hypodermic tablets for injections. 
Tablets remain popular as a dosage form because of the advantages, afforded both to 
the manufacturer [eg. simplicity & economy of preparation, stability and convenience 
in packing, shipping, and dispensing] and the patient [eg. accuracy of dosage, 
compactness, post ability, blendness of taste and ease of administration]. 
Although tablets are more frequently discoid in shape, they also may be round, oval, 
oblong, cylindrical or triangular. They may differ greatly in size and weight 
depending on the amount of drug substance present and the intended method of 
administration. 
Tabletting formulations: 
In the tablet-pressing process, it is important that all ingredients be fairly dry, 
powdered or granular, somewhat uniform in particle size, and freely flowing. Mixed 
particle sized powders can segregate during manufacturing operations due to different 
densities, which can result in tablets with poor drug or active pharmaceutical 
ingredient (API) content uniformity but granulation should prevent this. Content 
uniformity ensures that the same API dose is delivered with each tablet. 
Some APIs may be tabletted as pure substances, but this is rarely the case; most 
formulations include excipients. Normally, an pharmacologically inactive ingredient 
(excipient) termed a binder is added to help hold the tablet together and give it 
strength. A wide variety of binders may be used, some common ones including 
lactose, dibasic calcium phosphate, sucrose, corn, maize, starch, microcrystalline 
cellulose and modified cellulose (for eg. hydroxypropyl methylcellulose). Often, an 
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ingredient is also needed to act as a disintegrant to aid tablet disperssion once 
swallowed, releasing the API for absorption. Some binders, such as starch and 
cellulose, are also excellent disintegrants. 
Small amounts of lubricants are usually added, as well. The most common of these is 
magnesium stearate; however, other commonly used tablet lubricants include stearic 
acid, stearin, hydrogenated oil, and sodium stearyl fumarate. These help the tablets, 
once pressed, to be more easily ejected from the die. 
Properties of an ideal tablet: 
The objective of formulation and fabrication of tablet is to deliver the correct amount 
of drug in proper form at or over proper time. 
• Tablet should be elegant having its own identity and free from defects 
such as cracks, chips, contamination, discoloration etc. 
• It should have chemical and physical stability to maintain its physical 
integrity over time. 
• It should be capable to prevent any alteration in the chemical and 
physical properties of medicinal agent(s). 
• It should be capable of withstanding the rigors of mechanical shocks 
encountered in its production, packaging, shipping and dispensing. 
• An ideal tablet should be able to release the medicament(s) in body in 
predictable and reproducible manner. 
Advantages: 
• Tablets are unit dosage forms that provide an accurate, stable dose with 
greatest precision and least content variability. 
• Tablets are easy to use, handle and carry by the patient. 
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• Tablets are attractive and elegant in appearance. 
• Tablets are the most stable dosage form with respect to their physical, 
chemical and microbiological attributes. 
• The manufacturing cost of tablets is low as compared to other dosage 
form and their manufacturing speed is also quite high. 
• The packaging and shipping of tablets is comparatively easy and 
cheap. 
• The unpleasant taste and odour of medicament(s) can be easily masked 
by sugar coating. 
• The incompatibilities of medicament(s) and their deterioration due to 
environmental factors are less in case of tablet. 
• Whenever a fractional dose is required, tablets are divided into halves 
and quarters by drawing lines during manufacturing to facilitate 
breakage. 
• They are more suitable for large scale production than other oral 
dosage forms. 
• Tablets provide administration of even minute dose of drug in an 
accurate amount. 
• Their identification is probably the easiest because of variety of shapes 
and colors. 
• Tablets are formulated with certain special release profile products 
such as enteric or delayed release products. 
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Disadvantages: 
• Drugs that are amorphous in nature or have low density character are 
difficult to compress into tablet. 
• Hygroscopic drugs are not suitable candidate for compressed tablets. 
• Drugs having poor wetting properties, slow dissolution profile and 
high optimal gastro intestinal absorption are difficult or impossible to 
formulate as a tablet. 
• Drugs having bitter taste and objectionable odour requires special 
treatment like coating or encapsulation which may increase their 
production cost. 
• Drugs that are sensitive to oxygen or may also require certain 
treatment like special coating as well as packaging which may increase 
the overall manufacturing cost. 
• High dose drugs are difficult to formulate as tablet dosage form. 
• Some drugs which preferably get absorbed from the upper part of GIT 
may cause bioavailability problem in tablet dosage form. 
• Drugs that are liquid in nature are difficult to formulate as a tablet. 
• Swallowing of tablets especially by children and critically ill patients is 
very difficult. 
Tablet properties: 
Tablets can be made in virtually any shape, although requirements of patients and 
tabletting machines mean that most are round, oval or capsule shaped. More unusual 
shapes have been manufactured but patients find these harder to swallow, and they are 
more vulnerable to chipping or manufacturing problems. Tablet diameter and shape 
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are determined by the machine tooling used to produce them - a die plus an upper and 
a lower punch are required. This is called a station of tooling. The thickness is 
determined by the amount of tablet material and the position of the punches in relation 
to each other during compression. Once this is done, we can measure the 
corresponding pressure applied during compression. The shorter the distance between 
the punches, thickness, the greater the pressure applied during compression and 
sometimes the harder the tablet. Tablets need to be hard enough that they don’t break 
up in the bottle, yet friable enough that they disintegrate in the gastric tract. 
Lubricants prevent ingredients from clumping together and from sticking to the tablet 
punches or capsule filling machine. Lubricants also ensure that tablet formation and 
ejection can occur with low friction between the solid and die wall. Common minerals 
like talc or silica, and fats, eg. vegetable stearin, magnesium stearate or stearic acid 
are the most frequently used lubricants in tablets or hard gelatin capsules. 
TYPES OF TABLETS: 
Tablets are classified according to their route of administration or function. The 
following are the 4 main classification groups: 
1. Tablets ingested orally 
a) Compressed tablets 
b) Multiple compressed tablets 
c) Multi layered tablets 
d) Sustained action tablets 
e) Enteric coated tablets 
f) Sugar coated tablets 
g) Film coated tablets 
                                                                                                                                    Introduction 
 
Formulation & development of olmesartan medoxomil immediate release tablets Page 6 
 
h) Chewable tablets 
2. Tablets used in the oral cavity, Buccal tablets 
a) Sublingual tablets 
b) Lozenge tablets and torches 
c) Dental cones 
3. Tablets administered by other routes 
a) Implantation tablets 
b) Vaginal tablets 
4. Tablets used to prepare solutions 
a) Effervescent tablets, Molded tablets or tablet triturates (TT) 
b) Dispersible tablets (DT) 
c) Hypodermic tablets (HT) 
Compressed tablets: 
These tablets are uncoated and made by compression of granules. These tablets are 
usually intended to provide rapid disintegration and drug release. These tablets 
contain water-soluble drugs, which after swallowing get disintegrated in the stomach, 
and its drug contents are absorbed in the gastrointestinal tract and distribute in the 
whole body. 
Multiple compressed tablets: 
These tablets are prepared to separate physically or chemically incompatible 
ingredients or to produce repeated action, prolonged action products. To avoid 
incompatibility, the ingredients of the formulation except the incompatible materials 
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are compressed in to a tablet then incompatible substances along with necessary 
excipients are compressed in to a tablet. 
Multi layered tablets: 
These tablets consists of two or more layers of materials compressed successively in 
the same tablets. The color of each layer may be the same or different. The tablets 
having layers of different colors are known as “multicolored tablets”. 
Method of preparation of granules and tablets: [Aulton M.E, 2007] 
The manufacture of granulation for tablet compression may follow one or a 
combination of 3 established methods: 
Direct compression: 
In direct compression method the raw materials are size reduced and the required 
excipients are added and directly compressed. A few crystalline substances can be 
directly compressed into tablets. Tablet development of lower strength drugs may 
follow two processes either by traditional alcoholic or aqueous wet granulation 
technique or via the simple direct compression mode with marginally faster 
dissolution rates. Dosage strength with 1-10 mg per 100 or 150 mg tablet is 
considered suitable drug candidates for direct compression. 
Advantages: 
• Low labour input.  
• A dry process- advantage for those drugs, which degrade in moist 
conditions. 
• Fewer processing steps- leading reduced cost. 
• Direct compression dry blends are generally superior in dissolution 
than the equivalent wet granulation preparation incorporating up to 4% 
of super disintegrates. 
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Disadvantages: 
• Differences in the particle size and bulk density between the drug and 
diluents may lead to stratification within the granulation and leads to 
content non uniformity. 
• Direct compression diluents may interact with the drugs. 
• It’s not suitable for large dose drugs. 
• Because of dry nature of the process, static charge may develop during 
the processes of screening and mixing. 
Main Steps Involved in the direct compression method is: 
Milling of drugs and excipients 
 
Mixing 
 
Tablet compression 
Wet granulation: 
This is most widely used and the most general method of the tablet preparation. Its 
popularity is due to the greater possibility that granules will meet all physical 
requirements for the compression of good tablets. Most powders cannot be 
compressed directly into tablets because the lack of proper characteristics of binding 
or together into a compact entity. The donor processes ordinarily lubricated and 
disintegrating properties. Wet granulation is the process in which the liquid is added 
to powder equipped with any type of agitation that will produce agglomeration or 
granules. 
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Advantages: 
• The drugs having high dosage cohesiveness and compressibility of 
powder is improved due to the added binder that coats the individual 
powder particles, causing them adhere to each other so they can be 
formed into agglomerates called granules. During compaction process 
granules are fractured exposing fresh powder surface, which improves 
the compressibility. 
• Lower pressures are needed to compress tablets results in improving 
tool life. 
• Using wet method to obtain suitable flow and compression for 
cohesion must granulate drugs having high dosage and poor flow. 
• Good distribution and uniform content for soluble, low dosage drugs 
and color additives are obtained if they are dissolved in binder 
solution. 
• Bulky and dusty powders can be handled with out producing a great 
deal of dust and air borne contamination. 
• Controlled release dosage forms can be accomplished by selection of 
suitable binder and solvent. 
Limitations: 
• Because of large number of processing steps, it requires a large area 
with temperature and humidity control. 
• It requires a number of pieces of expensive equipment. 
• Greater possibility of material loss during processing due to transfer of 
material from one unit operation to the other. Time consuming, 
especially in wetting drying steps. 
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Main Steps involved in the Wet granulation method is: 
Sifting of Drugs and Excipients 
 
Mixing of Milled Powders.  
 
Preparation of Binder Solution.  
 
Mixing of Binder Solution with powder mixer to form wet mass then drying of Moist 
Granules 
                                                                     
Screening Dry Granules with Lubricant and Disintegrants 
 
Mixing of Screened Granules with Disintegrants and Lubricants for tablet 
compression 
 
Dry granulation: 
It is a valuable technique in situations where the effective dose of a drug is too high 
for direct compaction, and the drug is sensitive to heat, moisture, or both, which 
precludes wet granulation. This method involves the compaction of the components of 
a tablet formulation by means of a tablet press or specially designed machinery, 
followed by milling and screening, prior to final compression into tablet. When the 
initial blend of powders is forced into dies of large capacity tablet press and is 
compacted by means of flat faced punches, the compacted masses are called “slugs” 
and the process is referred to as “slugging”. On a large scale, “compression 
granulation”. 
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Main Steps Involved in the Dry granulation method is: 
    Milling of Drugs and Excipients 
 
  Mixing of Milled Powders.  
 
   Compression into large, hard tablets called slugs 
 
                                                       Screening of slugs 
 
 Mixing with lubricant and disintegrating agent 
 
                                   Tablet Compression. 
 
Excipients used in tablet formulation: [Lachmann and Libermenn, 2005] 
Excipient means any component other than the active pharmaceutical ingredient(s) 
intentionally added to the formulation of a dosage form. Many guidelines exist to aid 
in selection of nontoxic excipients such as IIG (Inactive Ingredient Guide), GRAS 
(Generally Regarded as Safe), Handbook of Pharmaceutical Excipients and others. 
While selecting excipients for any formulation following things should be considered 
wherever possible: 
keep the excipients to a minimum in number, minimize the quantity of each excipient 
and multifunctional excipients may be given preference over unifunctional excipients. 
Excipients play a crucial role in design of the delivery system, determining its quality 
and performance. Excipients though usually regarded as nontoxic there are examples 
of known excipient induced toxicities which include renal failure and death from 
diethylene glycol, osmotic diarrhoea caused by ingested mannitol, hypersensitivity 
reactions from lanolin and cardiotoxicity induced by propylene glycol. 
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Tablet excipients must meet certain criteria in formulation as follows: 
• They must be physiologically inert. 
• They must be acceptable to regulatory agencies. 
• They must be physically and chemically stable by themselves and in 
combination with the drugs and other tablet component. 
• They must be free of any bacteria considered to be pathogenic or 
otherwise objectionable. 
• They must not interfere with the bioavailability of the drug. 
• They must be commercially available in form and purity 
commensurate to pharmaceutical standards. 
• For drug products that are classified as food, such as vitamins, other 
dietary aids, and so on, the excipients must be approved as food 
additives. 
• Cost must be relatively inexpensive. 
• They must be non-toxic. 
• They must be commercially available in an acceptable grade in all 
countries where the product is to be manufactured. 
• They must not be contra-indicated by themselves eg. sucrose, or 
because of a component eg. sodium, in any segment of the population. 
• They must be color compatible, not produce any off color appearance. 
• They must have no deterious effect on the bioavailability of the drug in 
the product. 
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Binding agents: 
Binding agents play an important role in the manufacturing of tablets. Binding agents 
are also called as disintegrating agents. Binders are the glue that holds powder 
together to form granules. They are the adhesives that are added to tablet formulations 
to provide the cohesiveness required for the bonding together of the granules under 
compaction to form a tablet. The quantity used and the method of application must be 
carefully regulated, Since the tablet must remain intact until swallowed and must then 
release its medicament. 
Types of binding agents: 
Binders are either sugars or polymeric materials. The later fall into two classes: 
 Natural polymers: starches, or gums including acacia, tragacanth & gelatin. 
 Synthetic polymers: polyvinylpyrrolidone, methyl and ethyl cellulose, 
hydroxy propyl cellulose & povidone.  
Applications: 
• Wet binders: These are dissolved in a solvent (for eg. water or alcohol)      
and used in wet granulation process. 
        Ex: gelatin, cellulose, cellulose derivatives, PVP, starch, sucrose, PEG 
• Dry binders: These are added to the powder blend, either after a wet 
granulation Step, or as part of a direct powder compression formula. 
        Ex: cellulose, methylcellulose, PVP, PEG. 
Lubricants: 
Lubricants are used in tablet formulation to ease the ejection of the tablet from the die 
to prevent sticking of tablets to the punches and to prevent excessive wear on punches 
and dies. They function by interposing a film of lower shear strength at the interface 
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between the tablet and the die wall and the punch face. Lubricant should be carefully 
selected for efficiency and for the properties of the tablet formulations. 
Classification of Lubricants: 
Lubricants are classified according to their water solubility i.e. water insoluble and 
water soluble. Selection of lubricant depends partly on mode of administration, type 
of tablet, desired disintegration and dissolution properties, physicochemical properties 
of granules or powder and cost. 
Water Soluble Lubricants: 
Water Soluble Lubricants are used when a tablet is completely soluble or when 
unique disintegration and dissolution characteristics are required. Tablet containing 
soluble lubricant shows higher dissolution rate than tablet with insoluble lubricants. 
Physical mixture of this lubricant i.e. SLS or MLS with stearates can lead to the best 
compromise in terms of lubricity, tablet strength and disintegration. 
Water Insoluble Lubricants: 
Water insoluble lubricants are most effective and used at reduced concentration than 
water soluble lubricants. Since these lubricants function by coating, their effectiveness 
is related with their surface area, extent of particle size reduction, time and procedure 
of addition and length of mixing. 
Disintegrants: 
Disintegrants constitute a group of materials that, on contact with water, swell, 
hydrate, change in volume or form, or react chemically to produce a disruptive change 
in the tablet. Disintegrant is the term applied to various agents added to tablet 
granulation for the purpose of causing the compressed tablet to break apart 
[disintegrate] when placed in an aqueous environment. The major function of 
disintegrants is to oppose the efficiency of the tablet binder and the physical forces 
that act under compression to form the tablet. 
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The stronger the binder, the more effective must be the disintegrating agent in order 
for the tablet to release its medication. 
Ex: croscaramellose sodium, crospovidone, sodium starch glycolate. 
METHOD OF ADDITION OF DISINTEGRANTS: 
 
The requirement placed on the tablet disintegration should be clearly defined. The 
ideal disintegrant has, 
 
• Poor solubility. 
• Poor gel formation.  
• Good hydration capacity. 
• Good molding and flow properties.  
• No tendency to form complexes. 
Disintegrants are essentially added to tablet granulation for causing the compressed 
tablet to break or disintegrate when placed in aqueous environment. 
 
There are 2 methods used for incorporating disintegrating agents into tablets.  
Method 1: one-step method: 
This method involves: 
• External addition              
• Internal addition 
 
In external addition, the disintegrant is added to the sized granulation with mixing just 
prior to compression in internal addition. The disintegrants is mixed with other 
powder before wetting the powder mixture with the granulating solution. Thus the 
disintegrants is incorporated with the granule. 
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Method 2: Two-step method: 
In this method, a part of the disintegrant can be added internally and a part externally. 
This provides immediate disruption of the tablet into the previously compressed 
granules which the disintegrating agent with in the granules process further erosion of 
the granules to the original powder particles. Although this latter is an attractive 
theory, it is only partially effective in practice because any disintegrating agent bound 
with in the granules loses some of the disruptive force due to its encasement by the 
binder. Nevertheless, the 2-step method usually produces better and more complete 
disintegration than the usual method of adding the disintegrant to the granulation 
surface only. 
Super disintegrants in immediate release tablets: 
 
A disintegrant is an excipient which is added to a tablet or capsule blend to aid in the 
breakup of the compacted mass when it is put into a fluid environment. This is 
especially important for immediate release products where rapid release of drug 
substance is required. A disintegrant can be added to a powder blend for direct 
compression or encapsulation. It can also be used with products that are wet 
granulated. While there are some tablets fillers (starch, MCC) which aid in 
disintegration, there are more effective agents referred to as superdisintegrants. 
       
Ex: croscarmelose, crospovidone, and sodium starch glycolate. 
 
Diluents: 
Diluents are fillers comprise a heterogeneous group of substances, designed to 
makeup the required bulk of the tablet when the drug dosage itself is inadequate to 
produce the bulk. The dose of some drugs is sufficiently high that no filler is required. 
Ex: micro crystalline cellulose, lactose monohydrate, aspirin and certain antibiotics. 
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Tablet formulations may contain diluents for secondary reasons, to provide better 
tablet properties such as improved cohesion, to permit use of direct compression 
manufacturing, or to promote flow. 
Antiadherents, some materials have strong adhesive properties towards the metal of 
punches and dies or the tablet formulation containing excessive moisture which has 
tendency to result in picking and sticking problem. Therefore Antiadherents are 
added, which prevent sticking to punches and die walls. Talc, magnesium stearate and 
corn starch have excellent Antiadherents properties. Vegan had suggested that silicon 
oil can be used as Antiadherents. 
Glidants: 
 
Glidants are materials that improve the flow characteristics of granules by reducing 
the inter particulate friction. In proper amounts they also serve to assure smooth and 
uniform flow at all times. Glidants are useful in tablet formulations to attain free flow 
of granules, to permit use of direct compression or wet granulation for manufacturing 
process. Glidants give better control over the flow of the powder mixtures used to 
produce tablets and capsules with uniform and consistent flow. 
 
Ex: magnesium stearate, colloidal silicon dioxide, starch and talc.  
 
IMMEDIATE RELEASE DRUG DELIVERY SYSTEM: [LoydAllen V, 1999] 
Immediate release drug delivery system is also conventional type of drug delivery 
system and it is defined as - Immediate release tablets are designed to disintegrate and 
release their medicaments with no special rate controlling features such as special 
coatings and other techniques. 
Advantages of immediate release drug delivery systems: 
• Release the drug immediately. 
• More flexibility for adjusting the dose. 
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• It can be prepared with minimum dose of drug. 
• There is no dose dumping problem. 
• Immediate release drug delivery systems used in both initial stage and 
final stage of disease. 
Immediate release tablets (conventional tablets): The tablet is intended to be released 
rapidly after administration or the tablet is dissolved and administered as solution. It is 
the most common type and includes: 
• Orally disintegrating tablet 
• Sublingual tablet 
• Chewable tablet 
• Buccal tablet 
• Effervescent tablet 
Orally disintegrating tablets: 
Orally disintegrating tablets (ODT) are solid dosage forms that disintegrate in the oral 
cavity leaving an easy-to-swallow residue. The disintegration times are generally less 
than one minute. For orally disintegrating tablets, taste-masking of bitter or 
objectionably-tasting drug substances is critical. The taste-masking aspect plays a 
significant role in dissolution method development, specifications, and testing. The 
USP 2 paddle apparatus is the most suitable and common choice for orally 
disintegrating tablets. Discriminating, robust dissolution methods are extremely useful 
for monitoring process optimization and changes during scale-up of taste-masked bulk 
drug and tablet manufacture. 
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Sublingual Tablets: 
Tablets that disintegrate or dissolve rapidly in the patient’s mouth are convenient for 
young children, the elderly and patients with swallowing difficulties, and in situations 
where polatable liquids are not available. For these formulations, the small volume of 
saliva is usually sufficient to result in tablet disintegration in the oral cavity. The 
medication can then be absorbed partially or entirely into the systemic circulation 
from blood vessels in the sublingual mucosa, or it can be swallowed as a solution to 
be absorbed from the gastrointestinal tract. The sublingual route usually produces a 
faster onset of action than orally ingested tablets and the portion absorbed through the 
sublingual blood vessels bypasses the hepatic first-pass metabolic processes. 
Chewable tablets: 
The patients who have difficulty in swallowing tablets whole or for children who have 
not yet learnt to swallow a tablet, chewable tablet serves as an attractive alternative. 
The added advantage of this medication is that it can be taken at any time or when 
water is not available. Mannitol is normally used as a base due to low hygroscopy and 
more importantly, it gives pleasant, cooling sensation. Antacid tablets are invariably 
prepared as chewable to obtain quick ingestion relief as well as the antacid dose is too 
large to swallow and the activity is related to particle size. Another example is 
multivitamin tablet which a patient can take as a daily dose. 
Many of the excipients commonly used in tablet formulations are especially 
applicable for use in chewable tablets due to their ability to provide the necessary 
properties of sweetness and chewabilty. In general these fall into the sugar category, 
although a combination of excipients with artificial sweeteners may provide a 
satisfactory alternative. 
 
Uko-Nne and Mendes reported on the development of dried honey and molasses 
products marketed for use in chewable tablets. Both are free-flowing compressible 
materials with characteristics colours, odours and tastes that limit their primary 
applicability to the vitamin/food supplement field. 
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Buccal tablets: 
Tablets designed to dissolve on the buccal (cheek) mucous membrane were a 
precursor to the ODT. This dosage form was intended for drugs that yield low 
bioavailability through the digestive tract but are inconvenient to administer 
parenterally, such as steroids and narcotic analgesics. Absorption through the cheek 
allows the drug to bypass the digestive tract for rapid systemic distribution. Not all 
ODTs have buccal absorption and many have similar absorption and bioavailability to 
standard oral dosage forms with the primary route remaining GI absorption. However, 
a fast disintegration time and a small tablet weight can enhance absorption in the 
buccal area. The first ODTs disintegrated through effervescence rather than 
dissolution, and were designed to make taking vitamins more pleasant for children. 
This method was adapted to pharmaceutical use with the invention of microparticles 
containing a drug, which would be released upon effervescence of the tablet and 
swallowed by the patient.  
 
Effervescent tablets: 
Effervescent or Carbon tablets are tablets which are designed to break in contact with 
water or another liquid, releasing carbon dioxide in the process. Rapid break down 
often may cause the tablet to dissolve in to a solution, and is also often followed by a 
froth. These kind of tablets are usually used to deliver drugs or to encapsulate 
cleaning products, such as the enzymatic cleaners designed for wetsuits. 
These tablets are products of compression of component ingredients in to a dense 
mass, which is packaged in an airtight container or a blister pack. When is necessary, 
people can drop them in to water or another liquid to make a solution. Cleaning 
tablets may be added to filled tubs of water, depending on the packaging directions. 
From a drug delivery perspective, there are several advantages to effervescent tablets. 
One of the biggest advantage is that they deliver drugs to the body rapidly, because 
the drug is delivered in the form of a solution that is easy to absorb. Dosage control 
also is easier, and effervescent tablets can be used to protect certain ingredients from 
the highly acidic environment of the stomach.       
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DISEASE PROFILE: 
Blood Pressure: 
Blood pressure is the force of blood against the walls of arteries. Blood pressure is 
recorded as two numbers-the systolic pressure (as the heart beats) over the diastolic 
pressure (as the heart relaxes between beats). The measurement is written one above 
or before the other, with the systolic number on top and the diastolic number on the 
bottom. For example, a blood pressure measurement of 120/80 mmHg (millimeters of 
mercury) is expressed verbally as “120 over 80.” 
 
Fig.1: The arch of the aorta (main artery exiting the heart) and its branches 
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Table. 1: Classification of Blood pressure 
CONDITION 
Systolic pressure Diastolic pressure 
mmHg kPa mmHg kPa 
Normal 90-119 12-15.9 60-79 8.0-10.5 
Pre-hypertension 120-139 16.0-18.5 80-89 10.7-11.9 
Stage 1 140-159 18.7-21.2 90-99 12.0-13.2 
Stage 2 ≥160 ≥21.3 ≥100 ≥13.3 
Isolated systolic 
hypertension 
≥140 ≥18.7 <99 <12.0 
 
Blood pressure is usually classified based on the systolic and diastolic blood 
pressures. Systolic blood pressure is the blood pressure in vessels during a heart beat. 
Diastolic blood pressure is the pressure between heartbeats. A systolic or the diastolic 
blood pressure measurement higher than the accepted normal values for the age of the 
individual is classified as pre-hypertension or hypertension. 
Hypertension has several sub-classifications including, hypertension stage I, 
hypertension stage II, and isolated systolic hypertension. Isolated systolic 
hypertension refers to elevated systolic pressure with normal diastolic pressure and is 
common in the elderly. 
Causes 
Essential hypertension: 
Essential hypertension is the most prevalent hypertension type, affecting 90-95% of 
hypertensive patients. Although no direct cause has identified itself, there are many 
factors such as sedentary lifestyle, smoking, stress, visceral obesity, potassium 
deficiency (hypokalemia) obesity (more than 85% of cases occur in those with a body 
mass index greater than 25), salt (sodium) sensitivity, alcohol intake, and vitamin D 
deficiency that increase the risk of developing hypertension. Risk also increases with 
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aging, some inherited mutations, and having a family history of hypertension. An 
elevation of renin, a hormone secreted by the kidney, is another risk factor. 
Secondary hypertension: 
Secondary hypertension by definition results from an identifiable cause. This type is 
important to recognize since it’s treated differently to essential hypertension, by 
treating the underlying cause of the elevated blood pressure. Hypertension results in 
the compromise or imbalance of the path physiological mechanisms, such as the 
hormone-regulating endocrine system, that regulate blood plasma volume and heart 
function. Many conditions cause hypertension, some are common and well recognized 
secondary causes such as Cushing’s syndrome, which is a condition where the adrenal 
glands overproduce the hormone cortisol. 
Prevention: 
• Weight reduction and regular aerobic exercise (eg. walking): Regular 
exercise improves blood flow and helps to reduce the resting heart rate 
and blood pressure. 
• Reducing dietary sugar. 
• Reducing sodium (salt) in the diet: This step decreases blood pressure, 
many people use a salt substitute to reduce their salt intake. 
• Additional dietary changes beneficial to reducing blood pressure 
include the DASH diet (dietary approaches to stop hypertension) 
which is rich in fruits and vegetables and low-fat or fat-free dairy 
products. This diet has been shown to be effective based on research 
sponsored by the National Heart, Lung, and Blood Institute. In 
addition, an increase in dietary potassium, which offsets the effect of 
sodium has been shown to be highly effective in reducing blood 
pressure. 
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• Discontinuing tobacco use and alcohol consumption has been shown to 
lower blood pressure. 
Treatment 
Lifestyle modifications: 
The first line of treatment for hypertension is the same as the recommended 
preventative lifestyle changes such as the dietary changes, physical exercise, and 
weight loss, which have all been shown to significantly reduce blood pressure in 
people with hypertension. 
Medications: 
Several classes of medications, collectively referred to as antihypertensive drugs, are 
currently available for treating hypertension. Agents within a particular class 
generally share a similar pharmacological mechanism of action, and in many cases 
have an affinity for similar cellular receptors. An exception to this rule is the diuretics, 
which are grouped together for the sake of simplicity but actually exert their effects 
by a number of different mechanisms. Often multiple drugs are combined to achieve 
the goal blood pressure. Commonly used prescription drugs include: 
• ACE inhibitors (eg. captopril) 
• Alpha blockers (eg. prazosin) 
• Angiotensin II receptor antagonists (eg. losartan) 
• Beta blockers (eg. propranolol) 
• Calcium channel blockers (eg. verapamil) 
• Diuretics (eg. hydrochlorothiazide) 
• Direct renin inhibitors (eg. aliskiren) 
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Some examples of common combined prescription drug treatments include: 
• A fixed combination of an ACE inhibitor and a calcium channel 
blocker. One example of this is the combination of perindopril and 
amlodipine, the efficacy of which has been demonstrated in individuals 
with glucose intolerance or metabolic syndrome. 
• A fixed combination of an ACE inhibitor and a calcium channel 
blocker. 
• A fixed combination of a diuretic and an ARE. 
Combinations of an ACE inhibitor or angiotensin II-receptor antagonist, a diuretic and 
an NSAID (including selective COX-2 inhibitors and non-prescribed drugs such as 
ibuprofen) should be avoided whenever possible due to a high documented risk of 
acute renal failure. The combination is known as a “triple whammy” in the Australian 
health industry. 
In the present study Olmesartan medoxomil was choosed to develop immediate 
release tablets for treatment of hypertension. 
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REVIEW OF LITERATURE 
Rathnanand, et al, (2011)., Prepared and evaluated (in vitro) nizatidine immediate 
release tablets. The developed drug delivery system delivers a programmed dose of 
drug intended for excessively secreted gastric acid and for promoting healing of 
duodenal ulcers thereby spontaneously delivering the drug when exposed into GIT for 
producing an anti-ulcer effect. Accordingly, immediate release drug-containing core 
tablets of Nizatidine were prepared by wet granulation method. The obtained tablets 
were evaluated for weight variation, thickness, hardness, drug content, disintegration 
and in vitro dissolution studies. Stability studies of the optimized formulation was 
carried out as per ICH guidelines at 40 ± 2oC / 75 ±5% RH for one month and it was 
found to be stable. 
 
Sivasakthi, et al, (2011).,  Observed that  reverse phase-high performance Liquid 
chromatography method is a simple, accurate, precise and reproducible one. UV-
Spectrophotometric simultaneous equation method is adopted by official compendia 
for the stable substance that have reasonably broad absorption bands and which are 
practically unaffected by the variations of Instrumental parameters. A reverse phase 
high performance liquid chromatography method has been developed for the 
simultaneous estimation of Olmesartan medoxomil and Hydrochlorthiazide acid in 
tablet dosage form. The method was linear over the concentration range for 
Olmesartan medoxomil 5-70µg/ml and for Hydrochlorthiazide 5–50µg/ml. The mean 
recovery was found to be in the range of 98% to 102%. The Validation method was 
carried out using International Conference on Hormonisation Guidelines. The 
described RP-HPLC method was successfully employed for the analysis of 
Pharmaceutical formulations containing combined dosage form. 
 
Tiwari A.K, et al, (2011)., Prepared  and evaluated  the immediate release tablet of 
Drotaverine HCL by  Wet granulation method,  the  method has very high flow of 
powder blend that might create the problem of uneven dye filling. The 
Superdisintegrant AC-Di-Sol and Crospovidone were used for immediate release of 
drug from tablet. The coating was done to minimize the oxidation of Drotaverine 
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HCL. From the results, it can be concluded that increase in concentration of 
superdisintegrant will lead to decrease the disintegration time up to 8 min after 
coating without any change observed in the dissolution profile of drug. 
 
Vaishnani, et al, (2011)., Prepared various formulations of immediate release tablet 
of paroxetine using different superdisintegrants (sodium starch glycolate, 
croscarmellose, crospovidone)by wet granulation method. It is a selective serotonin 
reuptake inhibitor(SSRI) used in treatment of depression. Paroxetine have become 
first line drug in the pharmacotherapy of  patients with depression. This is because the 
drug possesses tolerability and safety advantages over the tricyclic agents.  Their 
results were found satisfactory. The invitro dissolution studies shows the release is in 
the following order of superdisintegrants: sodium starch glycolate > croscarmellose > 
crospovidone.   
 
Klaus O. Stumpe MD, et al, (2010)., Compared the antihypertensive efficacy of 
olmesartan with that of 4 other AURAS, at recommended maintenance doses, already 
in clinical use for the treatment of hypertension, the doses studied. These differences 
in blood pressure reduction between these agents may be clinically relevant and have 
important long-term implications. Additional studies will further define the role of 
olmesartan in the management of cardiovascular diseases, such as atherosclerosis. 
Mallion JM, et al, (2010)., Compared the efficacy and safety of olmesartan 
medoxomil (O) and ramipril (R) in elderly patients with essential arterial hypertension 
and concluded that in elderly patients with essential arterial hypertension, olmesartan 
provides an effective, prolonged and well tolerated blood pressure control with 
significantly better blood pressure normalization than ramipril and represents a useful 
option among first-line drug treatments of hypertension in this age group. 
Mire, et al, (2010)., Studied on angiotensin II (AT1) type 1 (AT1) receptor-mediated 
effects of A-IT play a key role in the pathophysiology of hypertension. Effective 
inhibition of A-IT is provided by the latest class of antihypertensive medications, the 
AT1 receptor blockers (ARBs). These orally available agents were developed around a 
common imidazole-based structural core. After oral administration, olmesartan 
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medoxomil is de-esterified in the intestinal tract to produce the active metabolite 
olmesartan, which undergoes no additional metabolic change. The marked 
antihypertensive efficacy of olmesartan medoxomil may result from a unique 
pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, 
long-lasting, dose-dependent blockade of A-IT. 
Miyoshi T, et al, (2010)., Evaluated the effects of angiotensin II type 1 receptor 
blocker (ARB) on arterial stiffness and its association with serum A-FABP in patients 
with hypertension. Thirty patients newly diagnosed with essential hypertension were 
treated with olmesartan (20mg/day), an ARB, for 6 months. Olmesartan treatment 
resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides 
a significant reduction of blood pressure. Olmesartan ameliorated arterial stiffness in 
patients with hypertension, which may be involved in the reduction of serum A-
FABP. 
Parambi, et al, (2010)., A simple, rapid, economical, accurate and precise method 
has been developed for estimation of Olmesartan medoxomil from tablet dosage form. 
The absorption maxima in THF solvent was found to be 265nm and Beer’s law was 
obeyed in a concentration range of 5-30mcg/ml and coefficient of correlation for 
Olmesartan was found to be 0.9997.The precisional accuracy of the developed 
method were confirmed by repeatability and recovery studies are validated 
statistically. The limit of detection and limit of quantitation of Olmesartan were found 
to be 0.23mcg/ml and 0.77mcg/ml respectively. The percentage recovery was found 
to be 99.37% for Olmesartan. The method showed good repeatability and recovery 
with relative standard deviation less than 2. So, this developed method can be used for 
the routine analysis of Olmesartan medoximil from formulations. 
 
Parikh B.N, et al, (2010)., Developed solid oral formulations of Telmisartan which 
can be prepared for long-lasting stability of the formulation under different climatic 
conditions and sufficient solubility of the active substance for sufficient 
gastrointestinal absorption in the slightly acidic and neutral pH region. Preferably, the 
formulations should have immediate release characteristics and a dissolution showing 
no essential pH dependency within the physiological relevant pH interval of the 
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gastrointestinal tract. Tablets were evaluated for various parameters like, weight 
variation, content uniformity, in-vitro dissolution studies were performed using 
United States Pharmacopeia (USP) apparatus type II. The effects of concentration of 
meglumine, povidone and different alkalizers on the release rate of Telmisartan were 
studied. Telmisartan has poor and pH dependent water solubility in order to enhance 
its dissolution different alkalizers were used and concluded that, significantly 
increased the drug dissolution rate in intestinal stimulated fluid (pH 7.5), slightly 
acidic (pH 1.2) and water. 
 
Punzi H, et al, (2010)., studied the use of ambulatory blood pressure (BP) monitoring 
(ABPM) to determine the efficacy of a fixed-dose combination of amlodipine (AML) 
and olmesartan medoxomil (OM) over the 24-hour dosing interval. This 12-week, 
titrate-to-goal study was conducted in 185 patients with hypertension. Patients were 
initially treated with AML 5 mg/day and up titrated to AML/OM 5/20, 5/40, and 
10/40 mg/day every 3 weeks if mean seated BP (SeBP) was >/=120/80 mmHg. An 
AML/OM-based titration regimen effectively reduces BP in patients with 
hypertension. 
Rana R, et al, (2010)., Found that Olmesartan medoxomil 20 mg once daily is not 
only effective in achieving the desired BP in a significant number of patients, it also 
shows excellent tolerability and hence compliance. Olmesartan is a valuable option 
for treatment of essential hypertension in adult patients. 
Rump LC, et al, (2010)., Observed that cardiovascular disease is a major cause of 
premature death and disability worldwide, and effective blood pressure (BP) control is 
crucial for the reduction of cardiovascular risk in patients with hypertension. Despite 
this, many will fail to attain recommended BP goals. A reappraisal of European 
guidelines led to revised recommendations for BP reduction to values with in the 
SBP/DBP range of 130-139/80-85 mmHg in all patients with hypertension, including 
higher-risk groups such as those with diabetes. 
Rump LC, et al, (2010)., Observed that high dose (40mg) olmesartan medoxomil 
(OM) blocks the angiotensin II receptor, significantly reducing blood pressure (BP). 
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Adding hydrochlorothiazide (HCTZ) to OM increases efficacy. Adding HCTZ to OM 
40mg significantly improves BP reductions and target BP rates in harder to treat 
patients and a clear dose-response was observed for efficacy. 
Tatsuya Suzuki, et al, (2010)., Performed dissolution test for the acetaminophen-
MCC (10:90) tablets. Dissolution profiles showed an interesting phenomenon, namely 
the dissolution rate of acetaminophen from MCC tablet decreased when the degree of 
crystallinity of MCC was in the range from 65.5 to 37.6%, however, it increased 
markedly when the degree of crystallinity of MCC was in the range from 25.8 to 
12.1%. The amount of water absorbed into tablets changed in accord with the 
dissolution rates of acetaminophen from tablets. The dissolution data indicate that 
drug release can be modified by changing the degree of crystallinity of MCC. 
Wilford Germino F, et al, (2010)., Worked and observed that angiotensin II receptor 
blockers (ARBs) are well tolerated and demonstrate significant BP reduction. 
Olmesartan medoxornil (OM), an ARB, has been well studied and achieves 
significant BP lowering and goal achievement with good tolerability. His review 
evaluates clinical efficacy and safety. Data from 5 OM-based studies: 4 dose-titration 
studies and 1 factorial study. Study results demonstrate that OM ± 
hydrochlorothiazide is highly effective in reducing BP while enabling a majority of 
patients with stage 1 hypertension to achieve BP goal. 
Choudhary D, et al, (2009)., Explained that, because to the poor water solubility of 
the Glipizide, its bioavailability is dissolution rate-limited. The purpose of this study 
was is to increase the solubility of Glipizide (GZ) in aqueous media by solid 
dispersion (SDs) technique with Poloxamer (PXM) 188 and Poloxamer (PXM) 407 
by using the kneading method No chemical interaction was found between GZ and 
PXM 188 or PXM 407 by the results of DSC. XRD and SEM studies show that PXM 
188 or PXM 407 inhibits the crystallization of GZ. The SDs prepared in this study 
were found to have better dissolution rates in comparision compared to intact GZ and 
physical mixture of PXM 188 or PXM 407 and GZ. It was found that the optimum 
weight ratio for drug:Carrier is 1:5 for PXM 188 and l:6 for PXM 4O7. 
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Durgacharan A Bhagwat, et al, (2009)., Demonstrated effect of release enhancers 
such as microcrystalline cellulose (MCC) and lactose on in-vitro drug release was also 
studied in sustained release tablets of verapamil. The results showed that PREC can 
be utilized as the matrix forming agent to sustain the release of VPH. More 
bioavailability was noted with the sustained release formulation even though the drug 
has substantial first pass metabolism. The results indicated that it is possible to make 
once a day sustained release tablet of VPH by using the melt granulation technique. 
Rai V.K, et al, (2009)., Prepared Raloxifene Hydrochloride immediate release tablets 
by wet granulation technique. In order to obtain the best, optimized product six 
different formulations were developed. Different filler, binder, disintegrant and 
lubricant were taken as variables. Weight variation, hardness, friability, disintegration 
time, in-vitro release and pharmaceutical assay were studied as response variables. 
Sticking was observed when the formulation containing stearic acid and sodium 
stearyl fumarate. How ever, in the remaing four formulations containing magnesium 
stearate, no sticking was observed. The different physical properties and in-vitro 
release profile showed best comparable with reference product. 
MallikarjunaSetty.C, et al, (2008)., Prepared aceclofenac fast-dispersible tablets by 
direct compression method. Effect of superdisintegrants (such as, croscarmellose 
sodium, sodium starch glycolate and crospovidone) on wetting time, disintegration 
time, drug content, in vitro release and stability parameters has been studied. 
Disintegration time and dissolution parameters (t50% and t80%) decreased with 
increase in the level of croscarmellose sodium. Whereas, disintegration time and 
dissolution parameters increased with increase in the level of sodium starch glycolate 
in tablets. It is concluded that fast-dispersible aceclofenac tablets could be prepared 
by direct compression using superdisintegrants. 
Mukeshgohel, et al, (2004)., Developed mouth dissolve tablets of nimesulide. 
Granules containing nimesulide, camphor, crospovidone, and lactose were prepared 
by wet granulation technique. Alternatively, tablets were first prepared percentage 
friability, wetting time, and disintegration time. The results of multiple linear 
regression analysis revealed that for obtaining a rapidly disintegrating dosage form, 
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tablets should be prepared using an optimum concentration of camphor and a higher 
percentage of crospovidone. The systematic formulation approach helped in 
understanding the effect of formulation processing variables. 
Perissutti, B, et al, (2003)., Reported preparation of fast release dosage form for 
carbamazepine involving the use of melt granulation process in high shear mixer for 
production of tablets. Crospovidone was used as releasing agent. The results showed 
enhancement of dissolution with intragranular addition of crospovidone, while extra 
granular addition of crospovidone causes fast disintegration. 
Ferrero.C, et al, (1997)., Investigated the efficiency of croscarmellose sodium (Ac-
DiSol®) in a direct compression formulation containing a poorly water soluble drug 
(albumin tanate) at high dose. An experimental design with two variables, applied 
pressure and concentration of Ac-Di-Sol®, allowed the evaluation of disintegration 
properties of the tablets. Tablet properties evaluated were affected by both variables, 
while compression parameters were essentially dependent on applied pressure. 
Desai D.S, et al, (1996)., Prepared combination wet granulated tablet formulation of 
an antihypertensive drug A and HCTZ containing povidone K-30 NF (PVP) as a 
binder and poloxamer 188 NF (Pluronic® F68) as a wetting agent. It was 
hypothesized that the mechanism of degradation of HCTZ in the presence of PVP 
and/or Pluronic® F68 was due to solubilization of the HCTZ by these excipients in 
the moisture present in tablets, followed by its hydrolysis. 
Van Kamp, et al, (1983)., Studied about the improvement of tabletting properties of 
super disintegrants by wet granulation. The crushing strength, disintegration and 
dissolution properties of tablets, made by wet granulation with lactose as filler, gelatin 
as binder, potato starch as disintegrant and magnesium stearate as lubricant would be 
markedly improved when potato starch (20%) was replaced by much lower 
concentration (4%) of an insoluble super disintegrant, such as SSG or crospovidone. 
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     AIM AND OBJECTIVE OF THE WORK 
AIM: The aim of this study is to formulate and develop immediate release tablet of olmesartan 
medoxomil. 
OBJECTIVE: The objective of this study is to obviate the demerits of slow release and slow 
absorption of normal tablets of olmesartan and to get immediate effect of the drug in the 
treatment of hypertension. 
To study the effect of super disintegrants on the release of olmesartan medoxomil. Different 
super disintegrants are used to attain immediate drug release and to give maximum therapeutic 
effect in short span of time when taken orally, finally to design a formulation of solid dosage 
form of olmesartan tablets with better stability of high product quality. 
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PLAN OF WORK 
The plan of the research work has been scheduled as: 
I. API and excipients characterization to prepare solid oral dosage form of 
olmesartan. 
II. Preformulation studies: 
o Compatability studies 
o Solubility 
o Angle of repose 
o Bulk density 
o Tapped density 
o Compressibility index 
o Hausners ratio 
o Moisture content 
III. Development of immediate release olmesartan tablets by wet granulation 
method. 
IV. Evaluation of the formulated tablets for their physiochemical characteristics 
such as: 
o Hardness 
o Thickness 
o Friability 
o Weight variation 
o Disintegration 
o Content uniformity 
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V. In-vitro drug dissolution study of the prepared tablets of olmesartan 
medoxomil.  
 
VI. Stability studies. 
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                                    DRUG PROFILE 
Chemical name : Olmesartan medoxomil (Wilson and Gisvold’s, 1998) is described chemically 
as 2,3-dihydroxy-2-butenyl 4(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-5-
ylphenyl)benzyl]imidazole5-carboxylate, cyclic 2,3-carbonate. 
 
Empherical formula : C29H30N6O6 
Molecular weight : 558.59 
Structural formula : The olmesartan molecule includes one tetrazole group (a 5-   member 
heterocyclic ring of four nitrogen and one carbon atom) and one imidazole group (a 5-membered 
planar heterocyclic aromatic ring of two nitrogen and three carbon atoms, classified as an 
alkaloid). 
 
 
Description : White to off-white crystalline powder 
Solubility : It is freely soluble in chloroform and in glacial acetic acid, slightly soluble in 
methanol and in acetonitrile and practically insoluble in water, ethyl acetate and in n-hexane. 
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CLINICAL PHARMACOLOGY 
Mechanism of action:  
Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the 
binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Olmesartan is a 
prodrug that works by blocking the binding of angiotensin II to the AT1 receptors in vascular 
muscle; it is therefore independent of angiotensin II synthesis pathways. By blocking the binding 
rather than the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback 
on renin secretion. As a result of this blockage, olmesartan reduces vasoconstriction and the 
secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing 
peripheral resistance. 
 
 
 
Fig.2: Renin-angiotension system showing site of action of angiotension converting enzyme            
inhibitors and angiotension II receptors blockers. 
ARBs 
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Pharmacokinetics: 
General: 
Olmesartan medoxomil is rapidly and completely bioactivated by ester hydrolysis to olmesartan 
during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype 
angiotensin II receptor antagonist. Olmesartan appears to be eliminated in a biphasic manner 
with a terminal elimination half-life of approximately 13 hours. The absolute bioavailability of 
olmesartan is approximately 26%. Food does not affect the bioavailability of olmesartan. After 
oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 
hours. 
Metabolism and Excretion: 
Following the rapid and complete conversion of olmesartan medoxomil to olmesartan during 
absorption, there is virtually no further metabolism of olmesartan. Total plasma clearance of 
olmesartan is 1.3 L/h, with a renal clearance of 0.6 L/h. Approximately 35% to 50% of the 
absorbed dose is recovered in urine while the remainder is eliminated in feces via the bile. 
Distribution: 
The volume of distribution of olmesartan is approximately 17 L. Olmesartan is highly bound to 
plasma proteins (99%) and does not penetrate red blood cells. The protein binding is constant at 
plasma olmesartan concentrations well above the range achieved with recommended doses. 
Pharmacodynamic: 
Olmesartan medoxomil doses of 2.5 to 40 mg inhibit the pressor effects of angiotensin I infusion. 
The duration of the inhibitory effect was related to dose, with doses of olmesartan medoxomil > 
40 mg giving > 90% inhibition at 24 hours. 
Plasma concentrations of angiotensin I and angiotensin II and plasma renin activity (PRA) 
increase after single and repeated administration of olmesartan medoxomil to healthy subjects 
and hypertensive patients. Repeated administration of up to 80 mg olmesartan medoxomil had 
minimal influence on aldosterone levels and no effect on serum potassium. 
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Dosage and administration: 
Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once 
daily when used as monotherapy in patients who are not volume-contracted. For patients 
requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may 
be increased to 40mg. Doses above 40mg do not appear to have greater effect. Twice-daily 
dosing offers no advantage over the same total dose given once daily. 
Side effects: 
Back pain, bronchitis, creatine phosphokinase increased, diarrhoea, headache, haematuria, 
hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis and 
sinusitis. 
Storage: 
Store at 20-25°C (68-77°F).  
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EXCIPIENTS PROFILE 
Following excipients (Hand book of pharmaceutical excipients, 5th edition by Raymond C Rowe, 
2005) are used in this wet granulation method. 
1. LACTOSE MONOHYDRATE 
Synonyms: Capsulac; granulac; lactochem; lactosum; monohydrate; pharmatose. 
Chemical name: O-β-D – galactopyranosyl - (1→4) – α – D-glucopyranose monohydrate. 
Empherical formula: C12H22O11.H20 
Functional category: Dry powder capsule diluents; tablet and capsule filler; Inhaler carrier; 
lyophilisation aid; tablet binder. 
Applications in pharmaceutical formulations: It is widely used as a filler and diluent in tablet 
and capsule and more limited extent in lipophilised products. Lactose is also used as a diluent in 
dry powder inhalations. 
Description: In the solid state, lactose appears as various isomeric forms, depending on the 
crystallization and drying conditions, i.e. α-lactose monohydrate, β-lactose anhydrous, and α-
lactose anhydrous. The stable crystalline forms of lactose are α-lactose monohydrate, β-lactose 
anhydrous, and stable α-lactose anhydrous. Lactose occurs as white to off-white crystalline 
particles or powder. Lactose is odorless and slightly sweet-tasting; α-lactose is approximately 
20% as sweet as sucrose, while β-lactose is 40% as sweet. 
 
Solubility: Freely but slowly soluble in water, soluble in ethanol, insoluble in alcohol. 
Stability and storage conditions: Mold growth may occur under humid conditions. 
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2. MICROCRYSTALLINE CELLULOSE 
Synonyms: Avicel H; cellets; cellulose gel; hellulosum microcrystallinum. 
Chemical name: Cellulose 
Empherical formula: ( C6H10O5)n 
Functional category: Adsorbent; suspending agent; tablet and capsule diluents; tablet 
disintegrant. 
Applications in pharmaceutical formulations: Microcrystalline cellulose is widely used in 
pharmaceuticals primarily as a binder/diluents in oral tablet and capsule formulations where it is 
used in both wet-granulation and direct compression processes. In addition to its as a 
binder/diluents microcrystalline cellulose has some lubricant and disintegrant properties that 
make it useful in tabletting. 
Description: Microcrystalline cellulose is a purified, partially depolymerised cellulose that 
occurs as white, odourless, tasteless, crystalline powder composed of porous particles. It is 
commercially available in different particle sizes and moisture grade different properties and 
applications. 
Solubility: Slightly soluble in 5% w/v sodium hydroxide solution practically insoluble in water, 
dilute acids and most organic solvents 
Stability and storage conditions: Microcrystalline cellulose is a stable though hygroscopic 
material. The bulk material should be stored in a well closed container in a cool, dry place. 
3. CROSCARMELLOSE SODIUM 
Synonym: AC-DI-SOL; carmellosum notricum conexum; cross linked carboxy methyl cellulose 
sodium. 
Chemical name: Cellulose, carboxy methyl ether, sodium salt.  
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Functional category: Tablet and capsule disintegrant. 
Empherical formula: C12H10Ca3O14 .4H2O 
Applications in pharmaceutical formulations: It is used in oral pharmaceutical formulations as 
a disintegrant for capsules, tablets and granules. 
Description: Croscarmellose sodium occurs as an odourless, white or greyish white powder. 
Solubility: Insoluble in water, although croscarmellose sodium rapidly swell to 4-8 times its 
original volume on contact with water. practically insoluble in acetone, ethanol and toluene. 
Stability and storage conditions: Croscarmellose sodium is a stable through hygroscopic 
material. 
A model tablet formulation prepared by direct compression, with croscarmellose sodim as a 
disintegrant, showed no significant difference in drug dissolution after storage at 30°C for 14 
months. Croscarmellose sodium should be stored in a well closed container in a cool and dry 
place. 
4. MAGNESIUM STEARATE 
Synonyms: Dibasic magnesium stearate; magnesium di stearate; magnesium salt; steric acid. 
Chemical name: Octadecanoic acid magnesium salt. 
Empherical formula: C36H70MgO4 
Functional category: Tablet and capsule lubricant. 
Applications in pharmaceutical formulations: Magnesium stearate is widely used in 
cosmetics, food and pharmaceutical formulations. It is primarily used as a lubricant in capsule 
and tablet manufacture at concentration between 0.25% and 5.0%w/w. 
                                                                                                                               Excipients profile 
 
Formulation & development of olmesartan medoxomil immediate release tablets Page 43 
 
Description: Magnesium stearate is a very fine, light white, precipitated or milled, powder of 
low bulk density, having a faint odour of stearic acid and a characteristic taste .The powder is 
greasy to touch and readily adhere to the skin. 
Solubility: Practically insoluble in ethanol (95%), ether and water, slightly soluble in warm 
benzene and ethanol. 
Stability and storage conditions: Magnesium stearate is stable and should be stored in a well 
closed container in cool and dry place. 
5.CROSPOVIDONE 
Synonyms: Crosslinked povidone; Kollidon CL; Kollidon CL-M; Polyplasdone XL;   
Polyplasdone XL 10; polyvinylpolypyrrolidone; 1-vinyl-2-pyrrolidinone homopolymer. 
 
Chemical name: 1-Ethenyl-2-pyrrolidinone homopolymer 
Empherical formula: (C6H9NO)n 
Functional category: Tablet disintegrant. 
Applications in pharmaceutical formulations: Crospovidone is a water-insoluble tablet 
disintegrant and dissolution agent used at 2–5% concentration in tablets prepared by direct 
compression or wet and dry granulation methods. It rapidly exhibits high capillary activity and 
pronounced hydration capacity, with little tendency to form gels. Studies suggest that the particle 
size of crospovidone strongly influences disintegration of analgesic tablets. Larger particles 
provide a faster disintegration than smaller particles. Crospovidone can also be used as a 
solubility enhancer. With the technique of co-evaporation, crospovidone can be used to enhance 
the solubility of poorly soluble drugs. The drug is adsorbed on to crospovidone in the presence of 
a suitable solvent and the solvent is then evaporated. This technique results in faster dissolution 
rate. 
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Description: Crospovidone is a white to creamy-white, finely divided, freeflowing, practically 
tasteless, odorless or nearly odorless, hygroscopic powder. 
 
Solubility: Practically insoluble in water, in alcohol, and in methylene chloride.  
 
Stability and storage conditions: Since crospovidone is hygroscopic, it should be stored in an 
airtight container in a cool, dry place. 
 
6. POVIDONE 
Synonyms: Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; 
polyvinylpyrrolidone; 1-vinyl-2-pyrrolidinone polymer. 
 
Chemical name: 1-Ethenyl-2-pyrrolidinone homopolymer 
Empherical formula: (C6H9NO)n 
Functional category: Disintegrant; dissolution aid; suspending agent; tablet binder. 
Applications in pharmaceutical formulations: Although povidone is used in a variety of 
pharmaceutical formulations, it is primarily used in solid-dosage forms. In tableting, povidone 
solutions are used as binders in wet granulation processes. Povidone is also added to powder 
blends in the dry form and granulated insitu by the addition of water, alcohol, or hydroalcoholic 
solutions. Povidone is used as a solubilizer in oral and parenteral formulations and has been 
shown to enhance dissolution of poorly soluble drugs from solid dosage forms. Povidone 
solutions may also be used as coating agents. Povidone is additionally used as a suspending, 
stabilizing, or viscosity-increasing agent in a number of topical and oral suspensions and 
solutions. The solubility of a number of poorly soluble active drugs may be increased by mixing 
with povidone. 
 
Description: Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30 are 
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manufactured by spray-drying and occur as spheres. Povidone K-90 and higher K-value 
povidones are manufactured by drum drying and occur as plates. 
 
Solubility: Soluble in cold water, butanol, acetone, ethyl alcohol, poly ethylene glycol, and 
hydroxylethyl pyrrolidine. 
 
Stability and storage conditions: Povidone darkens to some extent on heating at 1500C, with a 
reduction in aqueous solubility. It is stable to a short cycle of heat exposure around 110–1300C; 
steam sterilization of an aqueous solution does not alter its properties. Aqueous solutions are 
susceptible to mold growth and consequently require the addition of suitable preservatives. 
Povidone may be stored under ordinary conditions without undergoing decomposition or 
degradation. However, since the powder is hygroscopic, it should be stored in an airtight 
container in a cool, dry place. 
 
7. SODIUM STARCH GLYCOLATE 
Synonym: Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; starch 
carboxymethyl ether, sodium salt; Tablo; Vivastar P. 
 
Chemical name: Sodium carboxymethyl starch 
Functional category: Tablet and capsule disintegrant. 
Applications in pharmaceutical formulations: Sodium starch glycolate is widely used in oral 
pharmaceuticals as a disintegrant in capsule  and tablet formulations. It is commonly used in 
tablets prepared by either direct compression  or wet granulation processes. 
 
Description: Sodium starch glycolate is a white to off-white, odorless, tasteless, free-flowing 
powder. The PhEur 2005 states that it consists of oval or spherical granules, 30–100 mm in 
diameter, with some less-spherical granules ranging from 10–35 mm in diameter. 
 
Solubilty:  Practically insoluble in water, insoluble  in most organic solvents. 
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Stability and storage conditions: Tablets prepared with sodium starch glycolate have good 
storage properties. Sodium starch glycolate is stable and should be stored in a well-closed 
container in order to protect it from wide variations of humidity and temperature, which may 
cause caking. The physical properties of sodium starch glycolate remain unchanged for up to 3–5 
years if it is stored at moderate temperatures and humidity. 
 
8.COLLOIDAL SILICON DIOXIDE 
Synonyms: Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica; light anhydrous 
silicic acid; silicic anhydride; silicon dioxide fumed; Wacker HDK. 
Chemical name: Silica 
Empherical formula: SiO2 
Functional category: Adsorbent; anticaking agent; emulsion stabilizer; glidant; suspending 
agent; tablet disintegrant; thermal stabilizer; viscosity-increasing agent. 
 
Applications in pharmaceutical formulations: Colloidal silicon dioxide is widely used in 
pharmaceuticals, cosmetics, and food products; Its small particle size and large specific surface 
area give it desirable flow characteristics that are exploited to improve the flow properties of dry 
powders in a number of processes such as tabletting. Colloidal silicon dioxide is also used to 
stabilize emulsions and as a thixotropic thickening and suspending agent in gels and semisolid 
preparations. With other ingredients of similar refractive index, transparent gels may be formed. 
The degree of viscosity increase depends on the polarity of the liquid (polar liquids generally 
require a greater concentration of colloidal silicon dioxide than nonpolar liquids). Viscosity is 
largely independent of temperature. However, changes to the pH of a system may affect the 
viscosity; In aerosols, other than those for inhalation, colloidal silicon dioxide is used to promote 
particulate suspension, eliminate hard settling, and minimize the clogging of spray nozzles. 
Colloidal silicon dioxide is also used as a tablet disintegrant and as an adsorbent dispersing agent 
for liquids in powders. Colloidal silicon dioxide is frequently added to suppository formulations 
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containing lipophilic excipients to increase viscosity, prevent sedimentation during molding, and 
decrease the release rate. Colloidal silicone dioxide is also used as an adsorbent during the 
preparation of wax microspheres; as a thickening agent for topical preparations; and has been 
used to aid the freeze-drying of nanocapsules and nanosphere suspensions. 
 
Description: Colloidal silicon dioxide is a submicroscopic fumed silica with a particle size of 
about 15 nm. It is a light, loose, bluish-whitecolored, odorless, tasteless, nongritty amorphous 
powder. 
 
Solubility: Practically insoluble in water and in acids, soluble in hot solutions of alkali 
hydroxides.  
Stability and storage conditions: Colloidal silicon dioxide is hygroscopic but adsorbs large 
quantities of water without liquefying. When used in aqueous systems at a pH 0-7.5, colloidal 
silicon dioxide is effective in increasing the viscosity of a system. However, at a pH greater than 
7.5 the viscosity-increasing properties of colloidal silicon dioxide are reduced; and at a pH 
greater than 10.7 this ability is lost entirely since the silicon dioxide dissolves to form 
silicates.Colloidal silicon dioxide powder should be stored in a well-closed container. Some 
grades of colloidal silicon dioxide have hydrophobic surface treatments that greatly minimize 
their hygroscopicity. 
 
9. STEARIC ACID 
Synonyms: Cetylacetic acid; Crodacid; E570; Edenor; Emersol; Hystrene; Industrene; Kortacid ; 
Pearl Steric; Pristerene; stereophonic acid; Tegostearic. 
 
Chemical name: Octadecanoic acid 
Empherical formula: C18H36O2 
Functional category: Emulsifying agent; solubilizing agent; tablet and capsule lubricant. 
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Applications in pharmaceutical formulations: Stearic acid is widely used in oral and topical 
pharmaceutical formulations. It is mainly used in oral formulations as a tablet and capsule 
lubricant; although it may also be used as a binder or in combination with shellac as a tablet 
coating. It has also been suggested that stearic acid may be used as a sustained-release drug 
carrier. In topical formulations, stearic acid is used as an emulsifying and solubilizing agent. 
When partially neutralized with alkalis or triethanolamine, stearic acid is used in the preparation 
of creams. The partially neutralized stearic acid forms a creamy base when mixed with 5–15 
times its own weight of aqueous liquid; the appearance and plasticity of the cream being 
determined by the proportion of alkali used. Stearic acid is used as the hardening agent in 
glycerin suppositories. Stearic acid is also widely used in cosmetics and food products. 
 
Description: Stearic acid is a hard, white or faintly yellow-colored, somewhat glossy, crystalline        
solid or a white or yellowish white powder. It has a slight odor and taste suggesting tallow. 
 
Solubility:  Soluble in water, diethyl ether, acetone, ethanol, dimethyl formamide.  
Stability and storage conditions: Stearic acid is a stable material; an antioxidant may also be 
added to it; The bulk material should be stored in a well-closed container in a cool, dry place. 
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METERIALS & METHODS 
Table.2: MATERIALS USED: 
S.No. Ingredients Category Source 
1 Olmesartan medoxomil Drug Celon labs pvt ltd. (Hyderabad) 
2 Micro crystalline cellulose Diluent Niebrim chemicals ltd. (Banglore) 
3 Lactose monohydrate Diluent Vijilakpharma (Mumbai) 
4 Povidone Binding agent ISP technologies (Banglore) 
5 Crospovidone Disintegrant Vijilakpharma (Mumbai) 
6 Croscaramellose sodium Disintegrant Niebrim chemicals (Banglore) 
7 Sodium starch glycolate Disintegrant SD fine chemicals (Hyderabad) 
8 Magnesium stearate Lubricant Niebrim chemicals (Banglore) 
9 Colloidal silicon dioxide Glidant Venkar labs pvt limited (Hyderabad) 
10 Stearic acid Lubricant Signet chemicals (Mumbai) 
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Table.3: EQUIPMENTS USED:        
NAME OF INSTRUMENT VENDOR 
Digital balance Wiggenhauser (Japan) 
Electronic balance Essae (Germany) 
Vibratory sifter SSPM (Mumbai) 
Rapid mixer granulator(RMG) SSPM (Mumbai) 
Hot air oven Heat control instruments & Co. (Switzerland) 
Friabilator USP Electrolab (Japan) 
UV-visible spectrophotometer Perkin Elmer (Germany) 
JR moisture balance Servell instruments (Banglore) 
Multi mill SSPM (Mumbai) 
Octagonal blender SSPM (Mumbai) 
8 and 16 station tablet compression machine Rimek (Japan) 
Disintegration Tester (USP) Tab Machines (Banglore) 
Mechanical Stirrer  Remi Motors (Mumbai) 
VernierCalliperse Mitutoyo Corporation 
FT-IR spectrophotometer Jasco (Japan) 
Dissolution Apparatus (USP) Type-II Electrolab (Mumbai) 
Hardness Tester Tab Machines (Kolkata) 
Tap density tester Campbell electronics (Mumbai) 
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PREFORMULATION STUDIES: 
DRUG-EXCIPIENTS COMPABILITY STUDIES: 
Drug was mixed with excipients in different ratios. About 5gm of blend was prepared, which 
were kept in 10ml white colored glass vials and packed properly. These vials are exposed to 
room temperature and 25±2oc/60±5% RH. Observations for physical appearance were made at 
zero weeks to 1 month, then the samples were withdrawn for analysis of appearance. The drug-
excipient interaction was investigated by FT-IR. 
FT-IR SPECTROSCOPY: 
Drug and excipients compatibility study is done by fourier transform infrared (FT-IR) 
spectroscopy. FT-IR spectra were obtained by using an FT-IR spectroscopy-410 (jasco-japan). 
The samples (pure drug and final formulation in 1:1 ratio) were previously ground and mixed 
thoroughly with KBr, an infrared transparent matrix at 1:5 (sample /KBr) ratio respectively. The 
KBr discs were prepared by compressing the powders at a pressure of 5 tons for 5 mins in a 
hydraulic press (40 scans were obtained at a resolution 4cm-1 from 4600-300 cm-1). 
The compatibility studies provide the frame work for the drugs combination with the excipients 
in the fabrication of the dosage form. The study was carried out to establish that the 
therapeutically active drug has not undergone any changes, after it has been subjected to 
processing steps during formulation of tablets. 
SOLUBILITY:  
1part of drug was taken and dissolved in 50ml of water, and found that the drug was insoluble in 
water, then 1 part of drug was taken and dissolved in 10ml of chloroform, the drug was soluble 
in chloroform and 1part of drug was taken and dissolved in 10ml of glacial acetic acid, the drug 
was found to be soluble then 1part of drug was taken and dissolved in 10ml of acidic buffer (pH 
1.2), the drug was freely soluble in acidic buffer. 
BULK DENSITY DETERMINATION: 
Exactly 50 gm of drug was weighed on digital balance and transferred into a 100 ml measuring 
cylinder. The volume occupied by the drug was recorded as the bulk volume. This is the bulk 
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volume and the bulk density was calculated. It is expressed in gm/cc and is given by, Db (gm/cc) 
=
Vb
M
, Where, M is the mass of drug in gm and Vb is the bulk volume of the drug. 
Bulk density was calculated using the formula. 
                         Bulk density = Weight of granules 
Bulk volume of granules 
 
TAPPED DENSITY DETERMINATION: 
An accurately weighed quantity of the Olmesartan medoxomil blend (W), was carefully poured 
into the graduated cylinder and the volume (Vo) was measured, then the graduated cylinder was 
closed with lid, set into the density determination apparatus. The density apparatus was set for 
500 taps and after that, the volume (Vf) was measured and continued operation till the two 
consecutive readings were equal. The volume of blend was used to calculate the tapped density, 
Hausner’s ratio and Carr’s Index. 
                     Tapped density = Weight of granules 
Tapped volume of granules 
 
ANGLE OF REPOSE: 
A cylinder was taken, one end it is open and other end closed. The granules then poured in to the 
cylinder nearly (10-20gms) and the tube was gradually withdrawn without any shaking to form 
heaping on the horizontal surface, once the heap is formed the height of the heap was measured 
the circumference of the circle was measured. From these the Ɵ was determined. 
The angle of repose was calculated by using the formula given below. 
Angle of Repose (θ) = tan-1 (h/r) 
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Where,   h = height of pile 
   r = radius of the base of the pile 
               θ = angle of repose 
CARR’S INDEX: 
Carr’s index is also known as compressibility. It is indirectly related to the relative flow rate, 
cohesiveness and particle size. It is simple, fast and popular method of predicting powder flow 
characteristics. 
Carr’s index was calculated by using the formula: 
      Carr’s Index = 
(Tapped density – bulk density) 
X 100 Tapped density 
 
HAUSNER’S RATIO: 
Hausner’s Ratio provides an indication of the degree of densification which could result from 
vibration of the feed hopper. Hausner’s ratio indicates the flow properties of the powder and 
measured by the ratio of tapped density to bulk density.  
Hauser’s ratio was calculated by using the formula. 
Hauser’s Ratio:  Tapped density / Bulk density 
Hauser’s Ratio:  VF/VO 
Where,    V0 = Initial volume 
                Vf = Final volume  
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MOISTURE CONTENT (OR) WATER BY KF: 
Around 50ml of methanol was taken in titration vessel and titrated with Karl Fischer reagent to 
end point. In a dry mortar, the pellets were ground to fine powder. Weighed accurately about 
0.5g of the sample, transferred quickly to the titration vessel, stiff to dissolve and titrated with 
Karl Fischer reagent to end point, pale yellow color was observed. 
Calculation: 
Moisture content = V × F × 100 
Weight of sample in mg 
 
Where,   F = factor of Karl Fischer reagent. 
   V = volume in ml of Karl Fischer reagent consumed for sample titration. 
 
FORMULATION OF IMMEDIATE RELEASE OLMESARTAN MEDOXOMIL 
TABLETS: 
Wet granulation method: 
Step I Sifting of Raw Materials: 
Olmesartan medoxomil, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, 
povidone, crospovidine, sodium starch glycolate were sifted through #40 mesh and mixed in 
poly bag for 15 mins.  
Step II Preparation of Binder solution: 
18gms of povidone was dissolved in sufficient quantity of water and mixed well by using 
mechanical stirrer for the preparation of binder solution.  
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Step III Wet Granulation: 
Transferred the sifted olmesartan, microcrystalline cellulose, croscarmellose sodium, 
crospovidone, sodium starch glycolate, lactose monohydrate into Rapid mixer granulator. Dry 
mixed the powders present in Rapid Mixer Granulator for 5 minutes without chopper on. Added 
the binder solution to dry mixed powder under beater mixing. After 5 minutes of mixing switch 
on the chopper at high speed which will enable to break the lumps into granules. If required add 
additional quantity of Purified water. 
Step IV Drying: 
The granules were dried at 65°C inlet temperature in fluid bed drier. After 20 minutes of drying, 
removed the bowel from Fluid bed drier and mixed with SS 316 rod. Started drying again till the 
exhaust temperature was 38°C then stoped the drying process. Sample was taken from the fluid 
bed drier bowl and checked the Loss on Drying by using LOD apparatus at 105°C till constant 
weight. It should be between 1.5-3.5%. 
Sifting of extra granular material: 
lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, crospovidine, sodium 
starch glycolate, were sifted through #40 mesh and mixed in poly bag for 15 mins. 
Step V Pre Blending and Final Blending: 
Dried, sized granules were loaded into the Octagonal blender then loaded the sifted extra 
granular raw materials into the blender and blended for 15-20 minutes and then Magnesium 
Stearate, colloidal silica, stearic acid were loaded into Octagonal blender, Blended for 5 minutes. 
Step VI Compression:  
The tablet machine was fixed with D type, 1.5×8mm round flat bevel edged tooling to the 16 
station rotary tablet machine as per the SOP. Finally the lubricated granules were then 
compressed in to tablets on a 16 station rotary machine to get a 400mg weight.  
 
 
                                                                                                                                     Materials & Methods 
 
Formulation & development of olmesartan medoxomil immediate release tablets Page 56 
 
Table.4: Formula for immediate release formulation 
 
 
Ingredients 
                                              Batch No: (mg/tab) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
                                      INTRA-GRANULATION 
Olmesartan 
medoxomil 40 40 40 40 40 40 40 40 40 40 
Micro crystalline 
cellulose 188 - 94 - 94 92 92 92 92 92 
Lactose 
monohydrate - 140 - 70 70 70 70 70 70 70 
Povidone 18 18 18 18 18 18 18 18 18 18 
Crospovidone - - - - - - - 7 - - 
Croscaramellose 
sodium - - - - - - - - 7 7 
Sodium starch 
glycolate - - - - - - 7 - - - 
Purified Water q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s 
                                        EXTRA-GRANULATION 
Micro crystalline 
cellulose - 188 94 188 94 92 92 92 92 92 
Lactose 
monohydrate 140 - 140 70 70 70 70 70 70 70 
Crospovidone - - - - - - - 7 - - 
Croscaramellose 
sodium - - - - - - - - 7 7 
Sodium starch 
glycolate 10 10 10 10 10 14 7 - - - 
Magnesium stearate 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 - 
Colloidal silicon 
dioxide 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Stearic acid - - - - - - - - - 2.5 
TOTAL 400 400 400 400 400 400 400 400 400 400 
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EVALUATION OF COMPRESSED TABLETS 
 
The evaluation of tablets includes, the nature of the active ingredient (identification), expected 
amount (assay), purity (related compounds), and uniformity of the amount of drug from tablet to 
tablet (uniformity of dosage units). 
In addition to these tests, some other tests such as friability, hardness, disintegration, etc. are also 
conducted. 
PHYSICAL APPEARANCE: 
The general appearance of tablets, its visual identity and overall elegance is essential for 
consumer acceptance. The control of general appearance of tablet involves measurement of 
number of attributes such as tablet size, shape, color, presence or absence of odor, taste, surface 
texture and consistency of any identification marks.  
HARDNESS TESTING: 
Hardness of the tablet was determined by Stock’s Monsanto hardness tester which consists of a 
barrel with a compressible spring. The pointer moves along the gauze in the barrel fracture. 
When a tablet is placed in a barrel it breaks at a force of compression on a tablet by guaze in the 
barrel fracture. The tablet hardness of 5 kg is considered as suitable for handling the tablet. 
THICKNESS:   
10 tablets were measured for their thickness and diameter with a Caliper, Thickness Gauge. 
Average thickness and diameter were calculated. 
FRIABILITY: 
The friability of tablets was determined by Roche Friabillator. 20 tablets were taken and 
weighed. After weighing, the tablets were placed in the Roche Friabillator and subjected to the 
combined effects of abrasion and shock by utilizing a plastic chamber that revolves at 25 rpm for 
minutes dropping the from a distance of six inches with each revolution. After operation the 
tablets were de-dusted and reweighed. 
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Friability was determined by 
F = 100 (1-Wo/ Wt) 
Where, 
                 Wo      = weight of tablets before friability test. 
                 Wt     =  weight of tablets after friability test. 
DISINTEGRATION TIME: 
6 tablets were taken and placed each tablet in each tube of 6 tubes with a base of metal sieve of a 
basket assembly of USP disintegration apparatus and operated. The apparatus temperature was 
maintained at 370±0.50c. The medium used is 0.1N Hcl (pH 1.2) buffer medium. The tablets are 
intended to disintegrate into coarse particles in the medium in specific time were noted and 
comparision to I.P standard. 
UNIFORMITY OF DOSAGE FORMS: 
This test was conducted to establish consistency in the content of active ingredient from tablet to 
tablet. There are generally two approaches for establishing this: 
• Weight variation 
• Content uniformity 
 
Weight Variation: 
 
20 tablets were individually weighed, calculated the average weight, and compared the 
individual tablet weights to the average. The tablets met the USP tests that were not more than 2 
tablets were outside the percentage limit and no tablets differed by more than 2 times the 
percentage limit. The maximum percentage difference allowed is 5% for average weight of 
tablets more than 324mg.  
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Content Uniformity: 
In this test, 20 tablets were randomly selected contained for drug, and 10 the tablets olmesartan 
medoxomil should contain not less than 85.0 % and not more than 115.0 % of the label claim. If 
one unit outside the range of 85 to 115% of the label claim and no units is outside 75 to 125% or 
if RSD> 6% or if both conditions prevail, test 20 additional units. 
ASSAY: 
Standard preparation: 
40mg of accurately weighed olmesartan medoxomil powder was taken and transferred in to 
100ml volumetric flask. Initially 10ml of 0.1N Hcl (pH 1.2) solution was added and shaken for 
10min. Then, volume was made up to 100ml with 0.1N Hcl (pH 1.2) solution. This solution was 
filtered, and 1ml of filtrate was suitably diluted to 10ml with same diluent to obtain 
concentration of 40 µg mL-1 respectively and analysed by using UV-visible spectrophotometer, 
measured at 265 nm. 
Sample preparation: 
Twenty tablets were powdered and weight equivalent to 40mg of olmesartan medoxomil. 
Powder was transferred in to 100ml volumetric flask. Initially 10ml of 0.1N Hcl (pH 1.2) 
solution was added and shaken for 10min. Then, volume was made up to 100ml with 0.1N Hcl 
(pH 1.2) solution. This solution was filtered, and 1ml of filtrate was suitably diluted to 10ml with 
same diluent to obtain concentration of 40 µg mL-1 respectively and analysed. Absorbance of 
each sample was measured at 265 nm using UV-visible spectrophotometer. The drug content of 
the sample was estimated from their standard curve.       
STANDARD CALIBRATION CURVE: 
Stock solution: 
Standard stock solution was prepared by weighing out 100mg of olmesartan and transferred to 
100ml volumetric flask. It was dissolved in 0.1N Hcl (pH 1.2) solution and made up to volume to 
get a concentration of 1mg/ml. spectral characteristics of olmesartan were studied by taking 
concentrations of 10, 20, 30, 40, 50 mcg/ml, final concentrations of 5, 10, 15, 20, 25, 30, 35, 40, 
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45 µg ml−1 obtained scanned by UV-visible spectrophotometer at λmax of 265nm. Calibration 
curve of absorbance versus concentration were studied by taking concentration ranging from 1-
40mcg/ml and data revealed that Beer’s law was obeyed between concentration range of 5-
45mcg/ml.                        
In-vitro DISSOLUTION TEST: 
In-vitro drug release studies for the prepared tablets were performed by USP dissolution 
apparatus, type-2 (paddle) and volume was made up to 900ml using 0.1N Hcl (pH 1.2) buffer. 
The apparatus is maintained at temperature 370 ± 0.50c. The rotation speed of paddle was 
adjusted to 50 rpm and the sample dilution was made 1ml to 10ml, replacing the volume by 
buffer medium with sampling time intervals of 15, 30, 45 and 60 min. The withdrawn samples 
were analysed by UV-visible spectrophotometer at 265nm. 
Preparation of 0.1N Hcl (pH 1.2) Buffer medium: 
8.5ml of concentrated Hcl was dissolved in 1000ml of distilled water, for the preparation of 0.1N 
Hcl (pH 1.2) Buffer medium. 
STABILITY STUDIES: 
The final formulation, F8 tablets were placed in HDPE container and kept in stability chamber. 
These studies were carried out for 3 months at storage conditions of 25 ± 20c / 60 ± 5% RH. 
After completion of 3 months time, the samples were withdrawn and checked out for stability of 
the product. 
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RESULTS 
 
 Table.5: DRUG–EXCIPIENTS COMPATIBILITY STUDIES 
              
S.NO INGREDIENTS RATIO 
DESCRIPTION 
 
         Initial 
After 1month    
at  
(25±2oc/60±5%RH) 
 
1 
 
 
Olmesartan medoxomil – API 
 
1 White to off 
white powder NCC 
2 
 
API + Micro crystalline cellulose 
 
1:5 Off white 
coloured powder 
 
NCC 
 
3 API + Lactose monohydrate 1:5 White to off 
white powder NCC 
4 API + Povidone 2:1 White to creamy 
white powder NCC 
5 API + Crospovidone 2:1 White to creamy 
white powder NCC 
6 API + Croscaramellose sodium 2:1 Off white 
coloured powder NCC 
7 API + Sodium starch glycolate 2:1 White to off 
white powder NCC 
8 API + Magnesium stearate 10:1 Off white 
coloured powder NCC 
9 API + Colloidal silica 10:1 Off white 
coloured powder NCC 
10 API + Stearic acid 10:1 White to off 
white powder NCC 
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Preformulation studies for API: 
Table.6: API RESULTS 
 
 
 
 
 
BULK DENSITY (gm/ml) 0.447 
TAPPED DENSITY (gm/ml) 0.563 
CARR’S INDEX (%) 20.60 
HAUSNER’S RATIO 1.259 
WATER CONTENT BY KF (%) 0.68 
MOISTURE CONTENT (%) 0.71 
ANGLE OF REPOSE (Ɵ) 31.2 
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 Table.7: BULK DENSITY, COMPRESSIBILITY INDEX, HAUSNER’S RATIO, ANGLE 
OF REPOSE OF OLMESARTAN MEDOXOMIL BLEND 
 
 
 
FORMU
LATION          
CODE 
BULK 
DENSITY 
(gm/ml) 
TAP 
DENSITY 
(gm/ml) 
COMPRESS
IBILITY 
INDEX (%) 
HAUSNER’S 
RATIO 
MOISTUR
E 
CONTENT 
(%) 
 
ANGLE 
OF 
REPOSE 
(degrees) 
 
F1 0.443±0.03  0.568±0.03 22.11±1.28 1.282±0.05 0.82 31.4±0.05 
F2 0.449±0.04 0.558±0.04 20.53±1.33 1.242±0.09 0.96 32.3±0.06 
F3 0.432±0.03 0.558±0.02 23.42±1.25 1.292±0.08 0.71 31.2±0.09 
F4 0.488±0.05 0.643±0.03 24.10±1.37 1.317±0.04 0.94 27.2±0.08 
F5 0.473±0.03 0.579±0.04 18.30±1.39 1.224±0.05 0.88 28.9±0.07 
F6 0.463±0.04 0.583±0.05 20.58±1.36 1.259±0.06 0.63 29.3±0.04 
F7 0.467±0.06 0.560±0.03 16.60±1.28 1.199±0.04 0.72 24.6±0.09 
F8 0.461±0.02 0.532±0.02 13.34±0.98 1.154±0.02 0.62 24.8±0.03 
F9 0.484±0.04 0.571±0.04 15.23±1.17 1.118±0.04 0.68 26.3±0.04 
F10 0.469±0.03 0.559±0.02 16.10±1.26 1.192±0.03 0.79 27.3±0.08 
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Table.8: HARDNESS OF OLMESARTAN MEDOXOMIL TABLETS FOR DIFFERENT 
FORMULATIONS 
 
 
 
                                                  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO FORMULATION     CODE 
HARDNESS OF 
TABLETS 
(Kg/cm2) 
1 F1 3.13±0.13 
2 F2 3.28±0.15 
3 F3 3.34±0.20 
4 F4 3.19±0.16 
5 F5 4.64±0.15 
6 F6 4.98±0.17 
7 F7 5.17±0.14 
8 F8 5.09±0.06 
9 F9 5.32±0.10 
10 F10 5.29±0.15 
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Table.9: THICKNESS OF OLMESARTAN  MEDOXOMIL TABLETS FOR 
DIFFERENT FORMULATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO FORMULATION     CODE 
THICKNESS OF 
TABLETS(mm) 
1 F1 4.12±0.014 
2 F2 4.18±0.018 
3 F3 4.21±0.017 
4 F4 4.34±0.014 
5 F5 4.27±0.016 
6 F6 3.99±0.015 
7 F7 4.08±0.013 
8 F8 4.11±0.006 
9 F9 4.17±0.008 
10 F10 4.28±0.007 
                                                                                                                                                Results  
 
Formulation & development of olmesartan medoxomil immediate release tablets Page 68 
 
Table.10: FRIABILITY OF OLMESARTAN MEDOXOMIL TABLETS FOR 
DIFFERENT FORMULATIONS 
 
 
 
 
 
 
 
 
 
 
S.NO FORMULATION     CODE 
FRIABILITY OF 
TABLETS (%) 
1 F1 0.812±0.023 
2 F2 0.998±0.054 
3 F3 1.016±0.041 
4 F4 0.967±0.033 
5 F5 0.513±0.053 
6 F6 0.597±0.031 
7 F7 0.432±0.026 
8 F8 0.397±0.017 
9 F9 0.416±0.021 
10                    F10 0.579±0.028 
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Table.11: AVERAGE WEIGHT OF OLMESARTAN MEDOXOMIL TABLETS FOR 
DIFFERENT FORMULATIONS 
              
 
 
                           
 
 
 
 
 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
S.NO FORMULATION     CODE 
AVERAGE 
WEIGHT OF 
TABLETS (mg) 
1 F1 401.2±0.13 
2 F2 400.4±0.17 
3 F3 402.5±0.13 
4 F4 403.7±0.18 
5 F5 405.2±0.17 
6 F6 402.7±0.19 
7 F7 401.9±0.16 
8 F8 400.3±0.12 
9 F9 399.7±0.17 
10 F10 406.2±0.16 
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Table.12: DISINTEGRATION TIME OF OLMESARTAN MEDOXOMIL TABLETS 
FOR DIFFERENT FORMULATIONS 
 
 
                     
            
 
 
 
 
 
 
 
 
 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO  FORMULATION     CODE 
DISINTEGRATION 
OF TABLETS (min) 
1 F1 2.32±0.06 
2 F2 2.19±0.04 
3 F3 1.57±0.05 
4 F4 2.02±0.08 
5 F5 1.24±0.07 
6 F6 1.12±0.09 
7 F7 0.58±0.08 
8 F8 0.39±0.02 
9 F9 0.48±0.05 
10 F10 0.51±0.04 
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Table.13: ASSAY  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNO FORMULATION CODE PERCENTAGE  DRUG 
CONTENT 
1 F1 98.6±0.20 
2 F2 97.9±0.18 
3 F3 98.4±0.19 
4 F4 97.8±0.17 
5 F5 98.1±0.25 
6 F6 98.9±0.23 
7 F7 99.2±0.22 
8 F8 99.8±0.16 
9 F9 99.5±0.19 
10 F10 98.7±0.18 
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Table.14: STANDARD CURVE OF OLMESARTAN MEDOXOMIL IN 0.1N HCL       
(PH 1.2) BUFFER MEDIUM 
S.NO CONCENTRATION (µg/ml) 
ABSORBANCE AT 
265 nm 
1 0 0 
2 5 0.184 
3 10 0.348 
4 15 0.526 
5 20 0.721 
6 25 0.901 
7 30 1.112 
8 35 1.346 
9 40 1.534 
10 45 1.732 
 
 
Fig.3: STANDARD CALIBRATION CURVE OF OLMESARTAN MEDOXOMIL  IN 
0.1N HCL (PH 1.2) BUFFER MEDIUM 
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Table.15: INVITRO DISSOLUTION PROFILE OF FORMULATION F1 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0 0 
2 15 34.6 + 0.13 
3 30 51.3 + 0.20 
4 45 71.2 + 0.18 
5 60 84.2 + 0.14 
 
 
 
Fig.4: INVITRO DISSOLUTION PROFILE OF FORMULATION F1 IN 0.1N HCL      
(PH 1.2) BUFFER MEDIUM 
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Table.16: INVITRO DISSOLUTION PROFILE OF FORMULATION F2 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0 0 
2 15 32.4 + 0.15 
3 30 49.3 + 0.11 
4 45 70.8 + 0.17 
5 60 82.9 + 0.13 
 
 
 
Fig.5: INVITRO DISSOLUTION PROFILE OF FORMULATION F2 IN 0.1N HCL      
(PH 1.2) BUFFER MEDIUM 
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Table.17: INVITRO DISSOLUTION PROFILE OF FORMULATION F3 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0    0 
2 15               35.2 + 0.13 
3 30               51.0 + 0.19 
4 45               69.8 + 0.15 
5 60               83.7 + 0.17 
 
 
 
Fig.6: INVITRO DISSOLUTION PROFILE OF FORMULATION F3 IN 0.1N HCL      
(PH 1.2) BUFFER MEDIUM 
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Table.18: INVITRO DISSOLUTION PROFILE OF FORMULATION F4 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0 0 
2 15 32.9 + 0.16 
3 30 51.3 + 0.14 
4 45 73.8 + 0.18 
5 60 86.9 + 0.17 
 
 
 
Fig.7: INVITRO DISSOLUTION PROFILE OF FORMULATION F4 IN 0.1N HCL      
(PH 1.2) BUFFER MEDIUM 
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Table.19: INVITRO DISSOLUTION PROFILE OF FORMULATION F5 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0 0 
2 15 40.7 + 0.13 
3 30 59.3 + 0.15 
4 45 80.1 + 0.16 
5 60 91.4 + 0.12 
 
 
 
Fig.8: INVITRO DISSOLUTION PROFILE OF FORMULATION F5 IN 0.1N HCL      
(PH 1.2) BUFFER MEDIUM 
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Table.20: INVITRO DISSOLUTION PROFILE OF FORMULATION F6 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0 0 
2 15 41.8 + 0.17 
3 30 60.3 + 0.14 
4 45 84.6 + 0.12 
5 60 92.8 + 0.11 
 
 
 
Fig.9: INVITRO DISSOLUTION PROFILE OF FORMULATION F6 IN 0.1N HCL      
(PH 1.2) BUFFER MEDIUM 
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Table.21: INVITRO DISSOLUTION PROFILE OF FORMULATION F7 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0 0 
2 15 40.9 + 0.12 
3 30 62.3 + 0.19 
4 45 86.9 + 0.18 
5 60 95.8 + 0.17 
 
 
           
    Fig.10:  INVITRO DISSOLUTION PROFILE OF FORMULATION F7 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
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Table.22: INVITRO DISSOLUTION PROFILE OF FORMULATION F8 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0 0 
2 15 55.6 + 0.12 
3 30 81.4 + 0.14 
4 45 93.6 + 0.16 
5 60 99.5 + 0.15 
 
 
 
Fig.11: INVITRO DISSOLUTION PROFILE OF FORMULATION F8 IN 0.1N HCL    
(PH 1.2) BUFFER MEDIUM 
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Table.23: INVITRO DISSOLUTION PROFILE OF FORMULATION F9 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0 0 
2 15 50.4 + 0.11 
3 30 77.6 + 0.18 
4 45 86.3 + 0.17 
5 60 94.9 + 0.15 
 
 
 
Fig.12: INVITRO DISSOLUTION PROFILE OF FORMULATION F9 IN 0.1N HCL    
(PH 1.2) BUFFER MEDIUM 
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Table.24: INVITRO DISSOLUTION PROFILE OF FORMULATION F10 IN 0.1N HCL 
(PH 1.2) BUFFER MEDIUM 
S.NO TIME IN MINUTES 
CUMULATIVE 
PERCENTAGE OF 
DRUG RELEASED 
1 0 0 
2 15 50.9 + 0.16 
3 30 78.6 + 0.11 
4 45 88.3 + 0.19 
5 60 96.5 + 0.15 
 
 
 
Fig.13: INVITRO DISSOLUTION PROFILE OF FORMULATION F10 IN 0.1N HCL   
(PH 1.2) BUFFER MEDIUM 
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Fig.14: COMPARISON OF
FORMULATIONS (F1 TO F10
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STABILITY STUDIES: 
 
Table.25: Physical and chemical parameters of Olmesartan medoxomil tablets of      
formulation F8 after one month and 3 months at 25±2°C/60±5% RH 
 
 
Parameter 
 
Initial After 1 month After 3 months 
 
Colour & Appearance 
 
White to white off 
round shaped 
tablets 
White to white off 
round shaped 
tablets 
White to white off 
round shaped 
tablets 
Assay (%) 99.8±0.16 99.8±0.17 99.7±0.19 
 
Avg.weight (mg) 
 
 
400.3±0.12 
 
 
400.1±0.14 
 
399.8±0.16 
 
Hardness (kg/cm2) 
 
 
5.09±0.06 
 
 
5.06±0.08 
 
 
5.02±0.09 
 
 
Thickness (mm) 
 
 
4.11±0.006 
 
 
4.11±0.007 
 
 
4.10±0.009 
 
 
Friability (%) 
 
0.397±0.017 0.422±0.021 0.435±0.027 
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 Table.26: Dissolution profiles of Olmesartan medoxomil tablets from formulation F8 after 
one month and 3 months at 25°C/60% RH 
 
Time 
interval 
(min) 
                                  Cumulative Percentage drug release 
 
 
Initial 
 
After 1 month 
 
After 3 months 
0 0 0        0 
15 55.6 + 0.12 54.8 + 0.18 53.6 + 0.17 
30 81.4 + 0.14 79.6 + 0.15 78.9 + 0.19 
45 93.6 + 0.16 91.9 + 0.11 90.1 + 0.15 
60 99.5 + 0.15 98.3 + 0.19 97.6 + 0.13 
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                                                                            DISCUSSION 
Immediate release tablet of Olmesartan medoxomil were successfully prepared by wet 
granulation using excipients microcrystalline cellulose, lactose monohydrate, povidone, 
crospovidone, croscaramellose sodium, sodium starch glycolate, magnesium stearate, colloidal 
silica, stearic acid. Formulations were evaluated for pre and post compression parameters.  
The FT-IR spectral analysis showed that there was no change of any characteristic peaks of pure 
drug olmesartan and excipients, which confirmed that the absence of chemical interaction 
between drug and excipients. 
The granules of the tablets were prepared by wet granulation method and evaluated for various 
physicochemical characteristics. The granules of different formulation were evaluated for angle 
of repose, bulk density and tapped density, compressibility index, hausner’s ratio. It showed that 
the results of all formulations of the granules were within limits and thus it confirmed that the 
granules have good flow property except F1, F2, F3 & F4. In these first four formulations 
microcrystalline cellulose and lactose monohydrate were incorporated unequally in both intra 
and extra granulation, have poor compressibility index. 
The post compression parameters such as thickness, disintegration time, hardness, friability, drug 
release, weight variation and drug content showed that the results of all formulations were in 
limits except F1, F2, F3 & F4. 
Formulations F1, F2, F3 & F4 have poor flow property. So that the physico-chemical parameters 
such as hardness of the tablet was not found satisfactory. And  the % friability of the tablet was 
out of the pharmacopoeial limit. Dissolution parameter for batches F1, F2, F3 & F4 was not 
satisfactory. In formulations from F5 microcrystalline cellulose and lactose monohydrate were 
incorporated equally of (1:1) ratio  in both intra and extra granulation. So that the physico-
chemical parameters such as hardness and % friability of the tablet were improved. The 
percentage drug release of formulation F5 was improved to be 91.4% at the end of 60min. Table 
no.19. 
In F6 for the improvement of % drug release, we increased the concentration of sodium starch 
glycolate in extragranulation. The percentage drug release of formulation F6 was improved to be 
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92.8% at the end of 60min. Table no.20. For further improvement of drug release in F7 
incorporated the superdisintegrant sodium starch glycolate equally in both intra and extra 
granulation. The percentage drug release of formulation F7 was to be 95.8% at the end of 60min. 
Table no.21. 
In F8 used the super disintegrant crospovidone were incorporated equally between the intra and 
extragranulation. The percentage drug release of formulation F8 was to be 99.5% at the end of 
60min. Table no.22. 
In F9 & F10 the effect of other super disintegrant, croscaramellose sodium were studied 
respectively with other super disintegrants such as crospovidone and sodium starch glycolate. In 
this crospovidone showed better percentage drug release than croscaramellose sodium and 
sodium starch glycolate. In formulation F10 release rate at the end of 60min was slightly 
improved when compared to F9 and we incorporated stearic acid instead of magnesium stearate 
in extragranulation in order to improve flow property but there was not found any changes when 
compared to other formulations. 
From the release profile result crospovidone can release drug faster compared to croscaramellose 
sodium and sodium starch glycolate. Crospovidone > Croscaramellose sodium > Sodium starch 
glycolate. 
In the present work efforts have been made to develop Olmesartan medoxomil immediate release 
tablets as an approach to enhance the drug release profile using Superdisintegrants. The results 
showed that the release of the drug was depended on different superdisintegrants used, in that 
crospovidone can release drug faster compared to croscaramellose sodium and sodium starch 
glycolate. And the best formulation (F8) containing 3.5% crospovidone showed minimum 
disintegration time and better drug release profile as compared to other formulations.             
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CONCLUSION 
Olmesartan medoxomil tablets were formulated by wet granulation method using lactose 
monohydrate as diluent, MCC as diluent, povidone as binding agent, crospovidone, 
croscaramellose sodium & sodium starch glycolate as super disintegrating agents and colloidal 
silica as glidant, magnesium stearate & stearic acid  as lubricant with good release profile for a 
specified period of time up to 1hr. 
Compatibility studies were carried out for the physical mixture and the drug was found to be 
compatible with all excipients used in different formulations. 
The granulation was compressed into tablets and were analysed for the parameters such as 
average weight, friability, thickness, hardness, disintegration and assay.   
Formulation containing crospovidone (14mg) shows rapid rate of disintegration and dissolution 
when compared with other formulations. 
The invitro dissolution profiles of F1 to F10 were found to have different percentage of drug 
release. The disintegration time for F8 tablets was relatively low (0.39min) and dissolution 
profile (99.5±0.15%) at the end of 60min. when compared to other formulations, F8 has better 
release profile and concluded that F8
 
was better formulation product. 
The stability studies were conducted for F8 tablets for 3 months, which were found to be stable 
and concluded that formulation F8 was better stable product with good quality. 
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